These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11069266)

  • 1. Investigations into geriatric psychiatry challenges: AAGP Senior Investigator Award 2000.
    Small GW
    Am J Geriatr Psychiatry; 2000; 8(4):276-83. PubMed ID: 11069266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional brain imaging to identify affected subjects genetically at risk for Alzheimer's disease.
    Rapoport SI
    Proc Natl Acad Sci U S A; 2000 May; 97(11):5696-8. PubMed ID: 10811924
    [No Abstract]   [Full Text] [Related]  

  • 3. Brain-imaging surrogate markers for detection and prevention of age-related memory loss.
    Small GW
    J Mol Neurosci; 2002; 19(1-2):17-21. PubMed ID: 12212776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Cognitive stress test" may yield early clues of preclinical AD.
    Hotz RL
    Am J Alzheimers Dis Other Demen; 2001; 16(1):9-10. PubMed ID: 11416956
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.
    Small GW
    J Clin Psychiatry; 1996; 57 Suppl 14():9-13. PubMed ID: 9024331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.
    Small GW; Ercoli LM; Silverman DH; Huang SC; Komo S; Bookheimer SY; Lavretsky H; Miller K; Siddarth P; Rasgon NL; Mazziotta JC; Saxena S; Wu HM; Mega MS; Cummings JL; Saunders AM; Pericak-Vance MA; Roses AD; Barrio JR; Phelps ME
    Proc Natl Acad Sci U S A; 2000 May; 97(11):6037-42. PubMed ID: 10811879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.
    Ercoli L; Siddarth P; Huang SC; Miller K; Bookheimer SY; Wright BC; Phelps ME; Small G
    Arch Gen Psychiatry; 2006 Apr; 63(4):442-8. PubMed ID: 16585474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of positron emission tomography in diagnosing Alzheimer's disease.
    J Neurosci Nurs; 1996 Aug; 28(4):275. PubMed ID: 8880604
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease.
    Small GW
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1561-6. PubMed ID: 12453673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimaging for diagnosis of dementia.
    Small GW; Leiter F
    J Clin Psychiatry; 1998; 59 Suppl 11():4-7. PubMed ID: 9731543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.
    Laws SM; Clarnette RM; Taddei K; Martins G; Paton A; Hallmayer J; Almeida OP; Groth DM; Gandy SE; Förstl H; Martins RN
    Mol Psychiatry; 2002; 7(7):768-75. PubMed ID: 12192621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of APOE genotype on clinical phenotype in Alzheimer disease.
    Borroni B; Di Luca M; Padovani A
    Neurology; 2007 Feb; 68(8):624; author reply 624. PubMed ID: 17310043
    [No Abstract]   [Full Text] [Related]  

  • 13. Discriminant analysis of brain imaging data identifies subjects with early Alzheimer's disease.
    Rapoport SI
    Int Psychogeriatr; 1997; 9 Suppl 1():229-35; discussion 247-52. PubMed ID: 9447444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population.
    Harris JM; Cumming AM; Craddock N; St Clair D; Lendon CL
    Neurosci Lett; 2000 Nov; 294(1):37-40. PubMed ID: 11044581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients.
    Lee KU; Lee JS; Kim KW; Jhoo JH; Lee DY; Yoon JC; Lee JH; Lee DS; Lee MC; Woo JI
    J Neuropsychiatry Clin Neurosci; 2003; 15(1):78-83. PubMed ID: 12556576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism.
    Lehtovirta M; Partanen J; Könönen M; Hiltunen J; Helisalmi S; Hartikainen P; Riekkinen P; Soininen H
    Dement Geriatr Cogn Disord; 2000; 11(1):29-35. PubMed ID: 10629359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of APOE genotypes in a memory clinic cohort.
    van der Flier WM; Pijnenburg YA; Schoonenboom SN; Dik MG; Blankenstein MA; Scheltens P
    Dement Geriatr Cogn Disord; 2008; 25(5):433-8. PubMed ID: 18401171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.
    Reiman EM; Caselli RJ; Chen K; Alexander GE; Bandy D; Frost J
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3334-9. PubMed ID: 11248079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association between the A2 allele of the HLA system and age at onset of Alzheimer's disease].
    Nourhashémi F; Gillette-Guyonnet S; Fort M; Andrieu S; Abbal M; Albarède JL; Vellas B
    Presse Med; 2003 Feb; 32(4):158-61. PubMed ID: 12610471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.